Advertisement

Topics

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia

20:01 EDT 9 Aug 2017 | Cancer Connect

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory […]

The post FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia appeared first on .

Original Article: FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia"

Quick Search
Advertisement